Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6814225 | 0.97 | P2RX7 (0.35) | P2RX7MAPK1PDPK1MAPTMEN1 | |
| SCHEMBL6698925 | 0.91 | MAPK1 (0.35) | P2RX7MAPK1PDPK1 | |
| SCHEMBL6700135 | 0.90 | MAPK1 (0.35) | P2RX7MAPK1HDAC6 | |
| SCHEMBL6700606 | 0.90 | CLPP (0.38) | P2RX7MAPK1PDPK1 | |
| SCHEMBL6702121 | 0.82 | ABCB1 (0.34) | P2RX7MAPK1PDPK1HDAC6MAPT | |
| SCHEMBL6699350 | 0.81 | P2RX7 (0.35) | P2RX7MAPK1PDE5A | |
| SCHEMBL6700334 | 0.76 | ABCB1 (0.36) | P2RX7MAPK1HDAC6 | |
| SCHEMBL6700986 | 0.75 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL6700612 | 0.72 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL6696647 | 0.72 | CLPP (0.35) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | P2RX7 404/4885MAPK1 1571/4885PDPK1 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.